Saboundji, Karima
Auliac, Jean-Bernard
Pérol, Maurice
François, Géraldine
Janicot, Henri
Marcq, Marie
Dubos-Arvis, Catherine
Renault, Aldo
Guisier, Florian
Odier, Luc
Gervais, Radj
Chouaïd, Christos
Article History
First Online: 23 July 2018
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: K. Saboundji: fees to attend scientific meetings (Astra-Zeneca). J.-B. Auliac: fees to attend scientific meetings, speak, organize research or consult from Boehringer-Ingelheim, Hoffman-Roche, MSD, Bristol-Myers Squibb and Pfizer. M. Pérol: Roche, Genentech, Eli Lilly, Pfizer, Boehringer-Ingelheim, Clovis Oncology, MSD, Bristol-Myers Squibb, Novartis, Pierre Fabre, Astra-Zeneca (Advisory Boards); Roche, Astra-Zeneca, Chugai (institutional grants); Eli Lilly, Roche, Astra-Zeneca, Pfizer, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Takeda (scientific meetings). A. Renault: Astra-Zeneca, Bristol-Myers Squibb, Novartis and Lilly. L. Odier: Lilly (Advisory Board), Pfizer (scientific meeting) and Amgen (scientific meeting). R. Gervais: fees for scientific meetings or advisory boards for Astra-Zeneca, Roche and Boehringer-Ingelheim. C. Chouaïd: fees to attend scientific meetings, speak, organize research or consult from Astra-Zeneca, Boehringer-Ingelheim, Roche and Clovis. G. François, H. Janicot, M. Marcq, C. Dubos-Arvis, and F. Guisier declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.